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The morphology of cervical cancer referred for definitive 
radio-chemotherapy varies considerably ranging from 
expansive tumours confined to the cervix (stage IB) to 
irregular and infiltrating tumours involving the parametria 
(stage IIB), further to  the pelvic wall (stage IIIB), or to the 
distal part of the vagina (stage IIIA). Bladder and rectum may 
also be involved (stage IVA) as well as the corpus uteri. In 
addition to this morphological heterogeneity at diagnosis, 
additional variability arises as significant tumour regression 
often occur already during the first 2-3 weeks of external 
beam radiotherapy (EBRT).  
Local tumour control in cervical cancer require significant 
dose which is achieved with the application of brachytherapy 
(BT), typically going from a dose level of about 45 Gy 
obtained with EBRT to a dose level of more than 90 Gy 
covering at least 90% of the target volume. Due to the steep 
dose gradients involved in BT even higher dose levels well 
above 100 Gy is then reached in the central part of the 
tumour.  
BT has traditionally been administered by use of fixed 
standard plans delivering certain doses to specific points 
defined in 2D in relation to the BT applicator (point-A) rather 
than adapted to the changing morphology of the cervix 
tumour. However, during the last decade a significant change 
in clinical practice has taken place towards using a dynamic 
target concept developed by the GEC ESTRO gynaecological 
working group. This 4D target concept enables the delivery of 
adaptive levels of BT dose to the tumour extension at both 
diagnosis (intermediate-risk CTV) and remaining tumour and 
cervix at time of BT (high-risk CTV). To obtain maximal 
advantage of the initial tumour regression during EBRT, but 
also to avoid deleterious repopulation, the application of BT 
is normally performed  during the final weeks of a 6-8 week 
overall treatment time. To fulfil the ambitious planning aims 
of reaching >90 Gy in the high-risk CTV and >60 Gy in the 
intermediate-risk CTV with out overdosing the near by organs 
at risk new application techniques for BT has been developed 
employing combined intracavitary-interstial applicators. In 
centres experienced in image guided BT the new 
intracavitary/interstitial technique is now employed in 
almost 50% of the patients. 
Single centre series with significant patient numbers have 
already demonstrated improved local control and survival 
with morphology adapted BT especially in large tumours even 
surpassing the effect found for concomitant cisplatin 15 years 
ago. In addition, the risk of severe urologic and gastro-
intestinal morbidity has been significantly reduced. 
Multicentre studies including quality of life endpoints are 
now maturing pointing to specific dose response curves for 
tumour control and dose effect curves for morbidity. These 
impending findings will further expand the therapeutic 
window in cervix cancer radiotherapy as these new principles 
for image guided BT with evidence based planning aims and 
constraints find their way into the clinics around the world. 
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Biologically individualized treatment by integration of 
biological data and respective adaptation of treatment is 
major field of research and has a great potential to prove the 
concept of personalized oncology to provide a benefit to 
patients. The potential benefit may result from descalation 
in patients with good-risk tumours, targeted escalation in 
intermediate-risk patients and assigning patients with high-
risk tumours to novel approaches to overcome radiation 
resistance. Innovations in functional imaging, biomarker 
research, data modelling, high-precision treatment planning 
and delivery within the context of better radiobiological 
understanding and careful consideration of established 
clinical factors enables translational and clincial research 
into dose painting, adaptation according to temporal changes 
and model-based treatment prescriptions.  
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Purpose/Objective: Image guided adaptive brachytherapy 
(IGABT), has transformed treatment for locally advanced 
cervical cancer considerably. Dose adaptation and combined 
intracavitary/interstitial (IC/IS) applicators have significantly 
changed dose and volume parameters for targets and organs 
at risk, resulting in improved outcomes. This study aimed to 
evaluate the impact of IC/IS brachytherapy on late morbidity 
on which, to date, there is little data. 
Materials and Methods: Seven hundred and thirty one 
patients with locally advanced cervical cancer were enrolled 
in the retroEMBRACE study from 12 institutions. Detailed 
information on grade 1-5 toxicity (CTCAE,V3.0) following 
IGABT was captured in 610 patients enrolled from 8 
institutions. These patients were analysed in the present 
study. Based on technique, patients were divided into two 
groups. One group (N=300) referred to as advanced adaptive 
(AD) included all patients from the empirical time point, 
when an institution used IC/IS technique systematically in 
more than 20% of the cases. The other group (N=310), 
referred to as limited adaptive (LA), included all other 
patients where the most frequent technique used was 
intracavitary. 
Results: Patient related factors such as age, FIGO stage, 
tumour width, lymph node status and follow up time were 
equally distributed between the groups. No difference in 
EBRT target volumes, doses and fractionation schedule was 
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found. Compared with the LA group, more patients in the AD 
group, were treated with IMRT; 17% vs. 6% (p<0.01), and 
nodal boost - 22% vs. 13% (p <0.01). For brachytherapy, more 
patients in the AD group were treated with HDR BT; 66% vs. 
52% (p<0.01), combined IC/IS technique - 47% vs. 4% 
(p<0.01), and MRI based dose planning - 97% vs. 66% 
(p<0.01).Compared with the LA group, average HR CTV 
volume was 6cm3 larger and average D90 for HR CTV was 9 Gy 
higher in the AD group (p<0.01). This target dose difference 
did not result in higher D2cm³, for rectum (p=0.12) or 
sigmoid (p=0.38) in the AD group. D2cm³ for bladder was on 
average 4 Gy lower in the AD group (p=0.07) (table 1). 
At a median follow-up of 40 (3-163) months no significant 
difference in late actuarial grade 2 to 5 bladder (p=0.63), 
gastro-intestinal (p=0.81) or vaginal morbidity (p=0.10) was 
found between the LD and AD groups. 
 
 
Conclusions: Advanced adaptation with combined IC/IS 
technique enables delivery of significantly higher radiation 
doses to the HR CTV D90 without increasing the D2cm³ to 
organs at risk or adding more late morbidity to treatment.  
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Purpose/Objective: In our department, an adaptive 
radiotherapy protocol is used for laryngeal cancer patients 
treated with IMRT on the larynx as well as the bilateral 
(elective) lymph nodes. The goal was to investigate the 
clinical feasibility and the impact of this protocol.  
Materials and Methods: Twenty-seven patients were 
included. During fraction 1-4 in week 1, and in three 
fractions in the weeks thereafter, a CBCT was acquired. For 
each CBCT, an automatic gray value registration based on a 
clipbox around the cervical vertebrae was performed using 
the Elekta XVI software (version 4.5.1). Setup corrections 
were performed following the extended No Action Level 
(eNAL) protocol1. Technologists evaluated the position of the 
larynx relative to the PTV and the laryngeal bony structures, 
after the correction based on the vertebrae. If a 
displacement of 5 mm or more was seen, the physician was 
contacted to decide whether or not a new planning CT-scan 
and adaptive re-planning were required (CTV-PTV margin of 5 
mm). The impact of this protocol on larynx set-up variations 
and resulting margins were assessed.  
Results: In a recent study2 it was demonstrated that due to 
non-rigid motion in larynx cancer patients, applying the eNAL 
protocol with once a week follow-up imaging and omitting 
the above described approach for plan adaptation, a 5 mm 
CTV-PTV margin for the larynx was not sufficiently large in 
the cranial-caudal (CC) direction (see Table 1). In the new 
protocol, apart from three times a week imaging and 
adaptive re-planning, the patients also got swallowing 
instructions during CT, CBCT and irradiation. For 11/27 
patients one or more new planning CTs were made. This 
resulted in smaller calculated margins than in the previous 
study (Table 1). 
Table 1: Population mean (m), random (s), and systematic (S) 
set-up errors and calculated CTV-PTV margins3. 
 
 eNAL (2012)2  eNAL + adaptive re-
planning (2014) 
LR(mm) CC(mm) AP(mm) LR(mm) CC(mm) AP(mm) 
µ  -0.3 0.3 0.8 -0.3 -0.4 0.4 
σ  2.0 2.8 2.0 1.2 2.6 1.9 
∑ 0.9 2.8 1.0 0.8 1.6 1.0 
Margin33.2 7.6 3.5 2.4 5.0 3.2 
 
Conclusions: Based on a clear decision protocol for the 
technologists, adaptive treatment of laryngeal cancer 
patients was successfully implemented in the clinical routine. 
The approach effectively reduced CTV-PTV-margins. New 
patients are currently being entered in the study and will be 
included in the final analyses. 
1. IJROBP 2007, 1586–1595 
2. IJROBP 2013, 401-406 
3. IJROBP 1999, 905-919  
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Purpose/Objective: Large changes in bladder shape and size 
during a course of radiotherapy (RT) make adaptive RT (ART) 
appealing in the treatment of this tumor site. We are 
conducting a multi-center clinical phase II trial of daily plan 
selection based ART for bladder cancer with the primary aim 
of reducing gastro-intestinal morbidity due to sparing of the 
bowel and the rectum. We here report early dose/volume 
outcomes from the first twenty patients treated in this trial. 
Materials and Methods: All twenty patients received 60 Gy in 
30 fractions to the bladder; in 13 of the patients the pelvic 
lymph nodes were simultaneously treated to 48 Gy. Cone-
beam CT (CBCT) image guidance was used for daily set-up 
and treatment was delivered by volumetric modulated arc 
therapy (VMAT). The first five fractions were delivered using 
large, population-based margins; the bladder contours from 
the CBCTs acquired prior to the first four fractions were used 
to create a library of three plans, corresponding to a small, 
medium and large size bladder. All patients were from 
fraction no. 6 treated using daily online plan selection, where 
the smallest plan covering the bladder was selected prior to 
each treatment delivery. Volume ratios of PTV for ART vs. 
non-ART averaged over the treatment course were 
calculated. DVHs for bowel cavity and rectum were derived 
by summation of the selected dose plans on the planning CT 
and these were compared to standard non-adaptive RT plans 
using population-based margins (20 mm Sup/Ant, 15 mm Post 
and 10 mm LR and Inf). 
